Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
VKTX Price/Volume Stats
| Current price | $42.25 | 52-week high | $99.41 |
| Prev. close | $41.49 | 52-week low | $17.23 |
| Day low | $41.98 | Volume | 8,838,800 |
| Day high | $45.00 | Avg. volume | 4,484,050 |
| 50-day MA | $57.81 | Dividend yield | N/A |
| 200-day MA | $61.71 | Market Cap | 4.71B |
VKTX Stock Price Chart Interactive Chart >
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
VKTX Price Returns
| 1-mo | -19.66% |
| 3-mo | -35.01% |
| 6-mo | -11.61% |
| 1-year | 122.37% |
| 3-year | 715.64% |
| 5-year | 383.96% |
| YTD | 127.03% |
| 2023 | 97.98% |
| 2022 | 104.35% |
| 2021 | -18.29% |
| 2020 | -29.80% |
| 2019 | 4.84% |
Loading social stream, please wait...